MedTrace Logo

Lapatinib Resistance in Patients With Breast Cancer

NCT00898573 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-10-02

No results posted yet for this study

Summary

RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about cancer and the development of drug resistance in patients.

PURPOSE: This research study is looking at lapatinib resistance in patients with breast cancer.

Conditions

Interventions

DRUG

lapatinib ditosylate

GENETIC

fluorescence in situ hybridization

GENETIC

gene expression analysis

GENETIC

mutation analysis

GENETIC

polymerase chain reaction

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

cell sorting

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Thomas Budd, MD · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

  • Balazs Halmos, MD · Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00898573 on ClinicalTrials.gov